Research Project · Health - Pediatric Oncology
2141-V11, an agonist anti-CD40 antibody, for relapsed pediatric tumors
Cannonball Kids' Cancercannonballkidscancer.org (opens in a new tab)Catalog updated
- Amount
- $200,000
- Program type
- Research Project
- Field
- Health - Pediatric Oncology
- Eligible career stages
- Not listed
About this program
The Cannonball Kids' Cancer Foundation, a nonprofit organization, is offering a $200,000 grant to study the efficacy of 2141-V11, an agonist anti-CD40 antibody, in treating relapsed pediatric tumors. The study will investigate the safety and potential of combining 2141-V11 with checkpoint inhibition to enhance immunotherapy in pediatric patients. Researchers affiliated with the Dana-Farber Cancer Institute are eligible to apply, with the study expected to be conducted over 3 years. Specific eligibility criteria for applicants are not provided, but the focus is on advancing pediatric cancer research.
In FundFit
Full eligibility
Source announcement
Similar programs
These details are in FundFit.